Literature DB >> 27942523

CONCERT-1, an additional piece in the puzzle of (bio)-(chemo)-radiation.

Pol Specenier1, Jan B Vermorken1.   

Abstract

Year:  2016        PMID： 27942523      PMCID： PMC5124631          DOI： 10.21037/atm.2016.11.25

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  9 in total

1.  Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.

Authors:  K Kian Ang; Qiang Zhang; David I Rosenthal; Phuc Felix Nguyen-Tan; Eric J Sherman; Randal S Weber; James M Galvin; James A Bonner; Jonathan Harris; Adel K El-Naggar; Maura L Gillison; Richard C Jordan; Andre A Konski; Wade L Thorstad; Andy Trotti; Jonathan J Beitler; Adam S Garden; William J Spanos; Sue S Yom; Rita S Axelrod
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

Review 2.  Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review.

Authors:  Primož Strojan; Jan B Vermorken; Jonathan J Beitler; Nabil F Saba; Missak Haigentz; Paolo Bossi; Francis P Worden; Johannes A Langendijk; Avraham Eisbruch; William M Mendenhall; Anne W M Lee; Louis B Harrison; Carol R Bradford; Robert Smee; Carl E Silver; Alessandra Rinaldo; Alfio Ferlito
Journal:  Head Neck       Date:  2015-07-14       Impact factor: 3.147

Review 3.  Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: a systematic review and meta-analysis of published studies.

Authors:  Fausto Petrelli; Andrea Coinu; Valentina Riboldi; Karen Borgonovo; Mara Ghilardi; Mary Cabiddu; Veronica Lonati; Enrico Sarti; Sandro Barni
Journal:  Oral Oncol       Date:  2014-08-28       Impact factor: 5.337

4.  Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double-blind, placebo-controlled study.

Authors:  Vincent Gregoire; Marc Hamoir; Changhu Chen; Madeleine Kane; Andrzej Kawecki; Pramod K Julka; Hung-Ming Wang; Srihari Prasad; Anil K D'Cruz; Ljiljana Radosevic-Jelic; Rejnish R Kumar; Stanislaw Korzeniowski; Jacek Fijuth; Jean-Pascal Machiels; Mark V Sellers; Ilian Tchakov; David Raben
Journal:  Radiother Oncol       Date:  2011-08-05       Impact factor: 6.280

5.  Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial.

Authors:  Ricard Mesía; Michael Henke; Andre Fortin; Heikki Minn; Alejandro Cesar Yunes Ancona; Anthony Cmelak; Avi B Markowitz; Sebastien J Hotte; Simron Singh; Anthony T C Chan; Marco C Merlano; Krzysztof Skladowski; Alicia Zhang; Kelly S Oliner; Ari VanderWalde; Jordi Giralt
Journal:  Lancet Oncol       Date:  2015-01-15       Impact factor: 41.316

6.  Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.

Authors:  Jordi Giralt; Jose Trigo; Sandra Nuyts; Mahmut Ozsahin; Krzysztof Skladowski; Georges Hatoum; Jean-Francois Daisne; Alejandro César Yunes Ancona; Anthony Cmelak; Ricard Mesía; Alicia Zhang; Kelly S Oliner; Ari VanderWalde
Journal:  Lancet Oncol       Date:  2015-01-15       Impact factor: 41.316

7.  Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage.

Authors:  Tanja Schneider-Merck; Jeroen J Lammerts van Bueren; Sven Berger; Kai Rossen; Patrick H C van Berkel; Stefanie Derer; Thomas Beyer; Stefan Lohse; Wim K Bleeker; Matthias Peipp; Paul W H I Parren; Jan G J van de Winkel; Thomas Valerius; Michael Dechant
Journal:  J Immunol       Date:  2009-11-30       Impact factor: 5.422

8.  Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial.

Authors:  Stefano Maria Magrini; Michela Buglione; Renzo Corvò; Luigi Pirtoli; Fabiola Paiar; Pietro Ponticelli; Alessia Petrucci; Almalina Bacigalupo; Monica Crociani; Luciana Lastrucci; Stefania Vecchio; Pierluigi Bonomo; Nadia Pasinetti; Luca Triggiani; Roberta Cavagnini; Loredana Costa; Sandro Tonoli; Marta Maddalo; Salvatore Grisanti
Journal:  J Clin Oncol       Date:  2015-12-07       Impact factor: 44.544

9.  Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.

Authors:  Renato G Martins; Upendra Parvathaneni; Julie E Bauman; Anand K Sharma; Luis E Raez; Michael A Papagikos; Furhan Yunus; Brenda F Kurland; Keith D Eaton; Jay J Liao; Eduardo Mendez; Neal Futran; David X Wang; Xiaoyu Chai; Sarah G Wallace; Melissa Austin; Rodney Schmidt; D Neil Hayes
Journal:  J Clin Oncol       Date:  2013-03-04       Impact factor: 44.544
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.